Prospective study validates PAM50 classifier for predicting progression risk in men under active surveillance, indicating its potential as a valuable tool.
The PAM50 basal-luminal subtyping shows promise as a molecular classification tool for predicting progression risk in PCa. This is one of the only prospective studies evaluating PAM50 subtyping for predicting cancer progression in a cohort of men undergoing AS for PCa.
No takes yet. Share an insight, caveat, or question.
Malpani et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: